Mora Samia, Otvos James D, Rifai Nader, Rosenson Robert S, Buring Julie E, Ridker Paul M
Division of Preventive Medicine,Brigham and Women's Hospital, 900 Commonwealth Avenue E, Boston, MA 02215, USA.
Circulation. 2009 Feb 24;119(7):931-9. doi: 10.1161/CIRCULATIONAHA.108.816181. Epub 2009 Feb 9.
Nuclear magnetic resonance (NMR) spectroscopy measures the number and size of lipoprotein particles instead of their cholesterol or triglyceride content, but its clinical utility is uncertain.
Baseline lipoproteins were measured by NMR in 27 673 initially healthy women followed up for incident cardiovascular disease (n=1015) over an 11-year period. After adjustment for nonlipid risk factors, hazard ratios and 95% confidence intervals for the top versus the bottom quintile of NMR-measured lipoprotein particle concentration (measured in particles per liter) were 2.51 (1.91 to 3.30) for low-density lipoprotein (LDL(NMR)), 0.91 (0.75 to 1.12) for high-density lipoprotein (HDL(NMR)), 1.71 (1.38 to 2.12) for very low-density lipoprotein (VLDL(NMR)), and 2.25 (1.80 to 2.81) for the LDL(NMR)/HDL(NMR) ratio. Similarly adjusted results for NMR-measured lipoprotein particle size (measured in nanometers) were 0.64 (0.52 to 0.79) for LDL(NMR) size, 0.65 (0.51 to 0.81) for HDL(NMR) size, and 1.37 (1.10 to 1.70) for VLDL(NMR) size. Hazard ratios for NMR measures were comparable but not superior to standard lipids (total cholesterol 2.08 [1.63 to 2.67], LDL cholesterol 1.74 [1.40 to 2.16], HDL cholesterol 0.52 [0.42 to 0.64], triglycerides 2.58 [1.95 to 3.41], non-HDL cholesterol 2.52 [1.95 to 3.25], total/HDL cholesterol ratio 2.82 [2.23 to 3.58]) and apolipoproteins (B(100) 2.57 [1.98 to 3.33], A-1 0.63 [0.52 to 0.77], and B(100)/A-1 ratio 2.79 [2.21 to 3.54]). Essentially no reclassification improvement was found with the addition of the LDL(NMR) particle concentration or apolipoprotein B(100) to a model that already included the total/HDL cholesterol ratio and nonlipid risk factors (net reclassification index 0% and 1.9%, respectively), nor did the addition of either variable result in a statistically significant improvement in the c-index.
In this prospective study of healthy women, cardiovascular disease risk prediction associated with lipoprotein profiles evaluated by NMR was comparable but not superior to that of standard lipids or apolipoproteins.
核磁共振(NMR)光谱法测量脂蛋白颗粒的数量和大小,而非其胆固醇或甘油三酯含量,但其临床实用性尚不确定。
对27673名起初健康的女性进行NMR基线脂蛋白测量,并在11年期间随访心血管疾病发病情况(n = 1015)。在对非脂质风险因素进行调整后,NMR测量的脂蛋白颗粒浓度(以每升颗粒数计)最高五分位数与最低五分位数相比的风险比及95%置信区间,低密度脂蛋白(LDL(NMR))为2.51(1.91至3.30),高密度脂蛋白(HDL(NMR))为0.91(0.75至1.12),极低密度脂蛋白(VLDL(NMR))为1.71(1.38至2.12),LDL(NMR)/HDL(NMR)比值为2.25(1.80至2.81)。同样经调整的NMR测量的脂蛋白颗粒大小(以纳米计)结果,LDL(NMR)大小为0.64(0.52至0.79),HDL(NMR)大小为0.65(0.51至0.81),VLDL(NMR)大小为1.37(1.10至1.70)。NMR测量指标的风险比与标准脂质(总胆固醇2.08 [1.63至2.67],低密度脂蛋白胆固醇1. 74 [1.40至2.16],高密度脂蛋白胆固醇0.52 [0.42至0.64],甘油三酯2.58 [1.95至3.41],非高密度脂蛋白胆固醇2.52 [1.95至3.25],总胆固醇/高密度脂蛋白胆固醇比值2.82 [2.23至3.58])及载脂蛋白(B(100) 2.57 [1.98至3.33],A - 1 0.63 [0.52至0.77],B(100)/A - 1比值2.79 [2.21至3.54])相当,但并不优于它们。在已包含总胆固醇/高密度脂蛋白胆固醇比值和非脂质风险因素的模型中加入LDL(NMR)颗粒浓度或载脂蛋白B(100)后,基本未发现重新分类改善情况(净重新分类指数分别为0%和1.9%),且加入这两个变量中的任何一个均未使c指数有统计学显著改善。
在这项针对健康女性的前瞻性研究中,通过NMR评估的脂蛋白谱与心血管疾病风险预测的相关性与标准脂质或载脂蛋白相当,但并不优于它们。